Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA.
Maturitas. 2012 Mar;71(3):221-6. doi: 10.1016/j.maturitas.2011.11.018. Epub 2011 Dec 22.
Several selective estrogen receptor modulators are in clinical development for postmenopausal osteoporosis. Bazedoxifene has shown significant reductions in vertebral and non-vertebral (in higher-risk women) fracture risk, with no evidence of breast or endometrial stimulation. Lasofoxifene has demonstrated significant reductions in vertebral and non-vertebral fracture risk, but has been associated with endometrial/uterine effects. Both selective estrogen receptor modulators were generally safe and well tolerated but have been associated with some "class effects" (e.g., hot flushes, venous thromboembolic events). A tissue selective estrogen complex partnering bazedoxifene with conjugated estrogens is under clinical investigation for the treatment of menopausal symptoms and osteoporosis prevention. Future directions in selective estrogen receptor modulator research include ospemifene and RAD 1901.
几种选择性雌激素受体调节剂正在开发用于治疗绝经后骨质疏松症。巴多昔芬可显著降低椎体和非椎体（高危女性）骨折风险，且无乳房或子宫内膜刺激的证据。拉索昔芬可显著降低椎体和非椎体骨折风险，但与子宫内膜/子宫作用有关。这两种选择性雌激素受体调节剂通常安全且耐受良好，但与一些“类效应”有关（例如热潮红、静脉血栓栓塞事件）。一种组织选择性雌激素复合物将巴多昔芬与结合雌激素联合用于治疗绝经症状和预防骨质疏松症的临床试验正在进行中。选择性雌激素受体调节剂研究的未来方向包括 ospemifene 和 RAD 1901。
